Quoin Pharmaceuticals Reports Increased Net Loss and Decline in Total Assets for Q1 2026

Quoin Pharmaceuticals Ltd. reported a net loss of $4.998 million for the first quarter of 2026, an increase from a loss of $3.812 million in the same period of the previous year. The company's total operating expenses rose to $5.131 million, up from $3.957 million in the first quarter of 2025, primarily driven by a 44.7% increase in research and development expenses, which reached $3.434 million. General and administrative expenses also increased by approximately 7.2% to $1.697 million, reflecting higher commercial expenses and payroll costs.

The company's financial position showed a decline in total assets, which decreased to $15.693 million as of March 31, 2026, from $20.391 million at the end of 2025. Current assets fell significantly, primarily due to a reduction in cash and cash equivalents, which stood at $3.125 million compared to $3.818 million at the end of the previous year. Quoin's accumulated deficit increased to approximately $76 million, raising concerns about its ability to continue as a going concern without additional funding.

Strategically, Quoin Pharmaceuticals is focused on advancing its lead product, QRX003, which is under clinical development for Netherton Syndrome. The company has opened six clinical sites in the U.S. and is expanding its international presence with sites in the UK, Spain, France, and the Netherlands. Additionally, Quoin has entered into nine commercial partnerships for QRX003 across 61 countries, although it has yet to generate any revenue from product sales. The company is also developing QRX009, a topical formulation of rapamycin, and plans to submit an Investigational New Drug application for this product in the third quarter of 2026.

Operationally, Quoin's research and development activities are central to its business model, with significant investments in clinical trials and partnerships with research institutions. The company incurred approximately $1.1 million in research and development expenses under its agreements with Therapeutics Inc. and other partners during the first quarter of 2026. However, the company faces liquidity risks, as it has historically funded its operations through equity and debt financing, and it may need to raise additional capital to support its ongoing development programs.

Looking ahead, Quoin Pharmaceuticals acknowledges the uncertainty surrounding its ability to secure further funding and the potential impact on its development timelines. The company is actively exploring various financing options, including public and private offerings, collaborations, and licensing arrangements. However, it cautions that there can be no assurance that it will be able to raise the necessary funds on favorable terms, which could significantly affect its operations and future prospects.